What happened with LYEL today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Lyell Immunopharma is a clinical-stage biotechnology company that modifies patients’ own T cells to recognize and attack cancer, an approach called CAR T-cell therapy. Its lead candidate, ronde-cel, targets large B-cell lymphoma and is in late-stage trials. Its other clinical candidate, LYL273, is in early-stage testing for metastatic colorectal cancer. Lyell manufactures ronde-cel at its LyFE facility in Bothell, Washington, and plans to move LYL273 production there.
Lyell has no approved products and has never earned revenue from product sales. It has funded operations mainly through investors and business-development activities, and needs more capital to complete clinical development. If its treatments gain approval, it intends to sell them through a commercial organization it builds or through third parties; it currently has no sales or distribution capabilities. Payment for treatment would depend partly on coverage and reimbursement from government and private health insurers.
Reaching product sales requires successful clinical trials, regulatory approval and reliable manufacturing at commercial scale. Lyell licenses LYL273 from ICT, but its rights exclude mainland China, Hong Kong, Macau and Taiwan.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Lyell's prospects hinge on ronde-cel's pivotal lymphoma trials and development of LYL273, licensed from ICT for its colorectal-cancer program.
Gilead Sciences supplies a direct test of Lyell's ronde-cel: its Kite business sells Yescarta (axi-cel) for large B-cell lymphoma, one of the treatments ronde-cel faces in its second-line pivotal trial. That comparison tests ronde-cel against a cell therapy already sold for these patients.
Bristol Myers Squibb's Breyanzi is a direct hurdle for Lyell: the company sells this CD19-targeted CAR T-cell therapy, and ronde-cel challenges it in the second-line pivotal lymphoma trial. Results against Breyanzi will show how ronde-cel compares in large B-cell lymphoma.
Caribou Biosciences is developing vispa-cel for relapsed or refractory B-cell lymphoma, overlapping the patients Lyell targets with ronde-cel. Watch its ANTLER Phase 1 results: vispa-cel targets CD19 using donor-derived CAR T cells, while ronde-cel uses patients' own cells and targets CD19 and CD20.
Allogene Therapeutics could compete with Lyell's patient-derived CAR T-cell treatments by developing donor-derived T-cell therapies for blood cancers. Its approach aims to supply ready-made treatments rather than make a separate therapy from each patient's cells.
Novartis's Kymriah is an approved CD19-targeted CAR T-cell therapy competing with Lyell's investigational ronde-cel for patients with relapsed or refractory large B-cell lymphoma.
Autolus Therapeutics offers Lyell a commercial reference for therapies made from patients' own T cells: it sells CD19-targeted AUCATZYL for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, while Lyell develops CD19/CD20-targeted ronde-cel for lymphoma. AUCATZYL sales and production at its Nucleus facility provide a view of adoption and manufacturing at commercial scale.
Cellectis is developing an alternative to Lyell's patient-derived lymphoma therapies: gene-edited CAR T cells from donors for non-Hodgkin lymphoma. Its UCART lymphoma program is the relevant one to watch, with cells designed to be frozen, stored and distributed as ready-made treatments.
Legend Biotech provides a commercial and manufacturing benchmark for Lyell's CAR T-cell pipeline through its marketed CARVYKTI and additional cell-therapy programs. Watch CARVYKTI commercialization and production; Legend shares the product's development, manufacturing and commercial economics with Janssen.
Iovance Biotherapeutics offers a delivery benchmark for Lyell's patient-derived CAR T-cell programs in solid tumors: it sells Amtagvi, made by expanding T cells taken from a patient's tumor, for previously treated adults with advanced melanoma. Its centralized manufacturing and shipment to authorized treatment centers show how individualized tumor-infiltrating lymphocyte (TIL) therapy reaches patients.
CytomX Therapeutics is developing a rival colorectal-cancer approach to Lyell's GCC-targeted LYL273: an antibody carrying a drug, directed at EpCAM and designed to activate in tumors. Its Phase 1 trial has moved beyond dose escalation, making further colorectal-cancer results a concrete comparison for Lyell's cell-therapy program.
Fed Interest Rate Decision
Lyell earns interest on its cash and marketable securities, so interest rates affect what the company earns while funding cancer-drug development.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher borrowing costs may make future financing more expensive for Lyell, while higher returns on reinvested cash may add interest income to help fund its trials.
If it comes in below expectations
Lower borrowing costs may make future financing less expensive for Lyell, while lower returns on reinvested cash may reduce interest income available to fund its trials.
Bristol-Myers Squibb Co. earningsBMY
Bristol Myers Squibb's report will show how Breyanzi sales and uptake are developing among large B-cell lymphoma patients, giving Lyell a read on the treatment market ronde-cel would enter.
Look at Breyanzi sales and what the company says about uptake. Growth would show that patients, physicians and hospitals are using this kind of cell therapy, giving Lyell's ronde-cel a more established market to compete in; weakness could point to barriers such as treatment logistics, coverage or competition, and raise the bar for ronde-cel to show a meaningful clinical advantage. The products are not interchangeable, and sales do not establish comparable efficacy.
CytomX Therapeutics, Inc. earningsCTMX
CytomX's report will show how its colorectal-cancer program is progressing, giving Lyell a view of another approach aimed at overlapping patients.
Look for clinical progress in CytomX's colorectal-cancer program and whether it continues to advance. Further progress would show another approach moving forward for these patients, meaning LYL273 would need convincing clinical evidence; a stall or setback could mean less competitive pressure, but would not establish that LYL273 works. The approaches use different targets and mechanisms, so their efficacy cannot be compared directly.
Lyell Immunopharma, Inc. earningsThis company
Lyell has no approved products and relies on its available funds to run trials; this report will show how trial spending and cash use affect the resources it has left.
Read operating cash use alongside cash, cash equivalents and marketable securities, then compare it with clinical progress. Slower cash use while trials advance would mean current funds can support more development; faster use and a shrinking balance without corresponding progress would bring financing sooner or put pressure on Lyell to slow or reduce trials.
Autolus Therapeutics plc earningsAUTL
Autolus's report will show whether sales and production of its patient-derived T-cell therapy AUCATZYL are scaling together, offering Lyell a reference for cell-therapy demand and manufacturing hurdles.
Read AUCATZYL sales alongside Autolus's comments on production capacity and supply. Rising sales with supply keeping pace would show a patient-derived T-cell therapy expanding demand and manufacturing together; sales growth with production constraints, or weak sales, would expose gaps among capacity, delivery and adoption. Lyell faces its own manufacturing and commercialization challenges with patient-derived therapies, but the products and diseases differ.
